ROLE OF LOW DOSE OF MIFEPRISTONE IN MANAGEMENT OF FIBROID IN PERIMENOPAUSAL WOMEN: A COMPARATIVE STUDY.

Abstract

Introduction: Uterine leiomyoma is the commonest benign gynaecological tumour occurring in upto20% to 80% of women reaching perimenopausal stage and 40% has symptoms severe enough to warrant therapy. Recent evidence suggests that progesterone is essential for maintenance and growth of uterine leiomyoma and that estrogen is required only for upregulation of progesterone receptors. Mifepristone is synthetic steroid, derived from norethindrone, progesterone receptor modulator with primarily antagonistic property. The present study aimed to evaluate the efficacy and safety of low dose of mifepristone in medical management of uterine leiomyoma

Materials and methods: the study is being conducted in obstetrics and gynecology department of PMCH. In 2 years, 100 patients with age between 40-50 years with multiple or single fibroid with symptoms requiring treatment with normal blood biochemistry profile were studied. Two groups were made, each of 50 patients. Group I was given mifepristone in dose of 25mg/day; and Group II was given mifepristone in dose of 10mg/day for 3 months. Patients were followed up at 3 months and 6 months of starting treatment.

Results: In both groups, there was decrease in size of fibroid, control of bleeding, improvement of symptoms and hemoglobin profile.

Conclusion: Low dose of mifepristone is useful for decreasing the size of fibroid, control of bleeding, improvement of hemoglobin profile and for medical management of fibroid.

Keywords: mifepristone, fibroid, management